Therapeutic Cancer Vaccines

该项目将为前列腺癌患者开发和测试一种新的基于细胞的抗癌疫苗。这项合作将涉及法国、意大利、奥地利和德国的研究人员。在临床试验中，将从患者身上取血，将患者的细胞转化为细胞疫苗，并用放射性示踪剂标记这些细胞，然后重新注射到宿主体内。然后，Peter MacCallum癌症中心血细胞治疗中心的澳大利亚研究人员将使用先进的诊断成像技术跟踪疫苗的性能，以确定疫苗在刺激人体自身防御机制以对抗癌症方面的效果如何。国际合作正在开发多种治疗方法，研究所将帮助确定哪种方法对对抗癌症最有效。彼得麦卡勒姆癌症中心是世界上最重要的这种类型的细胞跟踪研究中心。

This project will develop and test a new cell-based anticancer vaccine for patients with Prostate cancer. The collaboration will involve French, Italian, Austrian and German researchers. Blood will be taken from patients in the clinical trial, the patient's cells will be converted into a cell vaccine, and these cells will be labelled with a radioactive tracer and re-injected into the host. Australian researchers at the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre will then track the performance of the vaccine using advanced diagnostic imaging to determine how effective the vaccine is in stimulating the body's own defence mechanisms to fight the cancer. Multiple versions of the treatment are being developed by the international collaboration and the Institute will help determine which approach is most effective in combating cancer. The Peter MacCallum Cancer Centre is the foremost centre worldwide for this type of cell tracking study.